Concurrent Investment Advisors LLC Increases Stock Position in ADMA Biologics Inc $ADMA

Concurrent Investment Advisors LLC increased its position in ADMA Biologics Inc (NASDAQ:ADMA) by 9.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,095 shares of the biotechnology company’s stock after purchasing an additional 973 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in ADMA Biologics were worth $202,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in ADMA. Farther Finance Advisors LLC boosted its stake in shares of ADMA Biologics by 1,149.1% in the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 2,505 shares during the period. GAMMA Investing LLC boosted its stake in shares of ADMA Biologics by 251.6% in the first quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 4,715 shares during the period. Janney Montgomery Scott LLC boosted its stake in shares of ADMA Biologics by 7.4% in the first quarter. Janney Montgomery Scott LLC now owns 70,991 shares of the biotechnology company’s stock valued at $1,408,000 after purchasing an additional 4,865 shares during the period. Envestnet Portfolio Solutions Inc. purchased a new position in shares of ADMA Biologics in the first quarter valued at $240,000. Finally, Ausbil Investment Management Ltd boosted its stake in shares of ADMA Biologics by 1,215.1% in the first quarter. Ausbil Investment Management Ltd now owns 106,869 shares of the biotechnology company’s stock valued at $2,120,000 after purchasing an additional 98,743 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Stock Up 2.3%

Shares of NASDAQ:ADMA opened at $14.69 on Tuesday. The stock has a market capitalization of $3.51 billion, a price-to-earnings ratio of 17.08 and a beta of 0.47. ADMA Biologics Inc has a 1-year low of $13.50 and a 1-year high of $25.67. The company’s fifty day moving average is $15.96 and its two-hundred day moving average is $18.33. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.01. The company had revenue of $121.98 million for the quarter, compared to analysts’ expectations of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm’s revenue was up 13.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.13 earnings per share. Equities analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “buy (b-)” rating on shares of ADMA Biologics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. Based on data from MarketBeat, ADMA Biologics has an average rating of “Buy” and a consensus target price of $27.67.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.